---
title: 'Associate Director, Financial Planning & Analysis (FP&A) at Dyne Therapeutics'
canonical: 'https://feeny.ai/job/associate-director-financial-planning-analysis-fp-a-dyne-therapeutics-waltham-ce1kav783776'
type: 'job'
last_seen: '2026-10-19'
---

# Associate Director, Financial Planning & Analysis (FP&A) at Dyne Therapeutics

- **Company:** Dyne Therapeutics
- **Location:** Waltham, MA
- **Compensation:** $170k–$195k
- **Posted:** 2026-10-06
- **Last confirmed live:** 2026-10-19
- **Apply:** https://job-boards.greenhouse.io/dynetherapeutics/jobs/6218166004

## Job description

Company Overview:

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at [https://www.dyne-tx.com/](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DaBhdU0rLyxqDF5MLc_hIfw7usSG4P5AlGZUt689alyH6v7mzOmFdpd9s5X8DlnvZSiEkR5UEisX91xRDuQTa2VgG02ByJmFzR8fXOPz8Zi8%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825271389%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=J6tnBKJnocuFhoQSNnLD03mlmX8CCP4Ufz89Tz2BRqY%3D&reserved=0), and follow us on [X](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DLBKooGRVe4UrE2Sa6ReueOswzx2nXn5X8MuiTcNNQ_6lX0cFP8Xf24jpFASx3QmF9Qt-1g3RGsigqX34LIiwMg%3D%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825316922%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=1SaJTlzgJLAz3INco8zVJpHByglVu9H3uR4eaUUwqbY%3D&reserved=0), [LinkedIn](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DV9e03kLdDWSbh0_VwnuvS9iTb21RRXsSKiAaMEbducMXKsrR2S-Gw7FLuap5gHCzvcaUIvGPyAeg1wRzFGrqW9J_Z6Ha8bGtJaWV9voKp-c%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825339609%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bDmOn9uD5vB9%2F2LttEyLg%2BANoH6v3vDFv7SAwVdi%2BoI%3D&reserved=0) and [Facebook](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DCMyzCcuOkxGNqTNEki-upZwJJPBCJLp0a-MvjKwwfPo1XQp8XutL02Vy2Vg3ZmpnCYnPLhHxcgEzFeh-07gg_rWzXbiw64-AClVkXbKyKQs%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825359448%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=exQuTFG7FGBX1V0XPy4zSebLvhQUDksB19Nej8Eg3DQ%3D&reserved=0).

Role Summary:

The Associate Director, Financial Planning & Analysis (FP&A) provides financial planning, reporting, business insights, and analytical support across the organization. The Associate Director serves as a strategic business partner and finance systems leader, owning the administration, optimization, and evolution of FP&A reporting tools, planning applications, and financial data warehouse capabilities. This role partners closely with Accounting, IT, and business stakeholders to deliver scalable financial reporting, forecasting, and analytics solutions that improve transparency and support data-driven decision making. The Associate Director develops financial models, analyzes business performance and trends, and delivers actionable insights that support operational execution, portfolio investment decisions, resource allocation, and long-term growth strategies.

This position is based in Waltham, MA.

Primary Responsibilities Include:

Financial Planning, Forecasting & Analysis

- Collaborate with cross-functional teams to develop quarterly forecasts, annual budgets, and short- and long-range financial plans.
- Monitor budget versus actual performance and provide variance analysis, insights, and recommendations to business leaders.
- Build and maintain financial models to support KPI analysis, portfolio prioritization, commercial strategy, and investment decisions.
- Conduct scenario planning and investment analyses, including evaluation of resource allocation and buy-up investment opportunities.
- Perform balance sheet, P&L, cash flow, COGS, and CAPEX/fixed asset analyses to support operational and strategic decision making.

Financial Systems, Reporting & Business Intelligence

- Lead the development, enhancement, and ongoing management of FP&A systems, reporting tools, and financial data warehouse capabilities.
- Create and maintain financial dashboards that provide visibility into actual spending, purchase order commitments, and forecast assumptions.
- Partner with Accounting and IT to improve financial reporting processes and integrate financial data across enterprise systems.
- Develop automated reporting and analytics solutions that enable stakeholders to access timely, actionable financial insights.
- Ensure data integrity, consistency, and usability across financial planning and reporting platforms.

Business Partnership & Governance

- Serve as a trusted financial partner to functional leaders by providing actionable insights and recommendations that support business objectives.
- Review contracts and purchase requisitions to ensure alignment with approved budgets, financial policies, and forecast assumptions.
- Monitor and report on key performance indicators (KPIs) and business performance metrics.
- Support strategic and operational decision making through ad hoc financial analyses and business case development.

Strategic Initiatives & Continuous Improvement

- Assist in the preparation of financial materials for Audit Committee and Board of Directors meetings.
- Identify opportunities to improve financial processes, reporting efficiency, data quality, and planning capabilities.
- Lead or support cross-functional initiatives that enhance forecasting accuracy, operational effectiveness, and financial visibility.
- Drive continuous improvement through the implementation of scalable financial processes, systems, and analytics solutions.

Education and Skills Requirements:

- Bachelor’s degree in Finance, Accounting, Economics, Business Administration, or a related discipline; MBA, CPA, or other advanced degree/certification preferred.
- 8+ years of progressive experience in FP&A, corporate finance, business analysis, or related financial roles, preferably within biotechnology, pharmaceuticals, life sciences, or a growth-stage public company environment.
- Demonstrated experience supporting annual budgeting, forecasting, long-range planning, and financial reporting processes.
- Expertise in financial modeling, scenario analysis, variance analysis, and business performance management.
- Experience administering and optimizing financial planning, reporting, business intelligence, and enterprise financial systems.
- Experience working with financial data warehouses and partnering with IT teams on reporting and systems enhancement initiatives.
- Strong understanding of financial statements, including P&L, balance sheet, and cash flow analysis.
- Experience partnering effectively with Accounting, IT, and business stakeholders to deliver integrated financial solutions.
- Strong analytical, problem-solving, and critical-thinking skills with the ability to translate complex financial information into actionable business insights.
- Excellent communication and presentation skills with the ability to influence and build alignment across functions.
- Demonstrated ability to manage multiple priorities, lead process improvements, and drive results in a fast-paced environment.
- Advanced proficiency with Microsoft Excel and financial planning/reporting systems.
- Operates with sound judgment, accountability, and a collaborative approach while influencing cross-functional initiatives and supporting organizational objectives.

#LI-Onsite MA Pay Range $170,000—$195,000 USD

The pay range reflects the base pay range Dyne reasonably expects to pay for this role at the time of posting. Individual compensation depends on factors such as education, experience, job-related knowledge, and demonstrated skills.

The statements contained herein reflect general details as necessary to describe the principles functions for this job, the level of knowledge and skill typically required, and the scope of responsibility, but should not be considered an all-inclusive listing of work requirements.  Individuals may perform other duties as assigned, including work in other functional areas to cover absences or relief, to equalize peak work periods or otherwise balance workload.

Dyne Therapeutics is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.

## About Dyne Therapeutics

## Company Overview
- **One-liner**: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted nucleic acid therapies for genetically driven neuromuscular diseases using its proprietary FORCE™ platform.
- **Entity Type**: Public (NASDAQ: DYN)
- **Headquarters**: Waltham, Massachusetts, United States
- **Founded**: 2018
- **Founders**: Not publicly available (the company was co-founded by a team of scientists and entrepreneurs; individual names not surfaced in search results)

## Core Business
- **Primary industry**: Biotechnology / Biopharmaceuticals – rare neuromuscular disease therapeutics
- **Target customers**: B2B / B2G – regulatory agencies, healthcare providers, payers, and most importantly patients with Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease.
- **Mission / Purpose**: “Delivering functional improvement for people living with neuromuscular diseases.” [dyne-tx.com](https://www.dyne-tx.com/)

## Products & Services
Dyne’s pipeline is built around its FORCE™ platform, which uses an antigen-binding fragment (Fab) conjugated to transferrin receptor 1 (TfR1) to deliver therapeutic payloads to muscle and the central nervous system.

- **Z‑rostudirsen (DYNE‑251)** – An investigational therapeutic for DMD patients amenable to exon 51 skipping. Consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to an anti‑TfR1 Fab. Phase 1/2 DELIVER trial met primary endpoint; BLA submission for U.S. Accelerated Approval planned for Q2 2026 with potential launch in Q1 2027. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
- **Z‑basivarsen (DYNE‑101)** – Investigational therapeutic for DM1, using an antisense oligonucleotide (ASO) conjugated to anti‑TfR1 Fab. Phase 1/2 ACHIEVE trial fully enrolled; Phase 3 HARMONIA trial ongoing. [dyne-tx.com](https://www.dyne-tx.com/pipeline/)
- **DYNE‑302** – Preclinical candidate for FSHD, using an siRNA payload to suppress DUX4 expression. [dyne-tx.com](https://www.dyne-tx.com/pipeline/)
- **DMD Franchise Expansion** – Four additional development candidates (DYNE‑253, DYNE‑245, DYNE‑244, DYNE‑255) targeting exons 53, 45, 44, and 55 for DMD, entering IND‑enabling studies. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)

## Market Standing
- **Valuation / Market Cap**: Not disclosed in search results (public company; market cap fluctuates with stock price; current figure not provided in the sources).
- **Key Metric**: Cash, cash equivalents and marketable securities of **$1.1 billion** as of December 31, 2025, providing runway into Q1 2028. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
- **Notable Investors / Partners**: Not listed in provided search results (likely institutional investors; prior venture rounds not detailed here).
- **Growth Signals**:
  - Headcount grew **38.2% YoY** to **227 employees** (2025). [linkedin.com](https://www.linkedin.com/company/dynetx)
  - Positive topline results from DELIVER trial for z‑rostudirsen; potential first product launch in Q1 2027 if approved.
  - Advancing five distinct clinical/preclinical programs across multiple neuromuscular indications.

## Competitive Advantages
- **FORCE™ Platform**: Differentiated delivery technology that uses a TfR1‑binding Fab to enable broad and deep tissue penetration in both muscle and CNS – addressing one of the biggest hurdles in neuromuscular drug development.
- **Best‑in‑Class Potential**: Clinical data for z‑rostudirsen showed statistically significant dystrophin expression (5.46% of normal at 6 months, 7‑fold change) and preservation of lung function (FVC%p) compared to placebo, despite a small trial not powered for functional endpoints.
- **Broad Pipeline**: Covering multiple exon‑skipping opportunities in DMD as well as entirely different diseases (DM1, FSHD, Pompe) with the same core platform, reducing risk and enabling rapid expansion.

## Strategic Focus
- **Regulatory Submission**: File a Biologics License Application (BLA) for z‑rostudirsen in Q2 2026 under U.S. Accelerated Approval pathway.
- **Late‑Stage Trials**: Initiate two field‑defining Phase 3 confirmatory trials (FORZETTO for DMD and HARMONIA for DM1) in 2026 following FDA alignment on design.
- **Pipeline Expansion**: Move four additional DMD exon‑skipping candidates into IND‑enabling studies and advance preclinical DYNE‑302 (FSHD) toward the clinic.
- **Commercial Readiness**: Prepare for potential first‑ever company launch in Q1 2027 with a focus on U.S. market, while also pursuing ex‑U.S. approval pathways.

## Why Work Here
- **Mission‑Driven Culture**: The company’s “One Dyne community” ethos emphasizes accountability, transparency, fearlessness, and a relentless drive to deliver functional improvement for patients and families. [dyne-tx.com](https://www.dyne-tx.com/careers-culture/)
- **Competitive Benefits**: Medical, dental, vision, 401(k), flexible vacation, paid holidays including a year‑end office closure, short‑ & long‑term disability, HSA/FSA accounts. [dyne-tx.com](https://www.dyne-tx.com/careers-culture/)
- **Work Environment**: Office location in Waltham, MA (Boston area). Remote/hybrid policy not specified in search results; likely on‑site or hybrid for lab‑based roles. Career page lists roles such as Associate Director, Oligonucleotide Development; Scientist, RNA; Director of Training – reflecting a mix of research, clinical, and corporate functions. [job-boards.greenhouse.io](https://job-boards.greenhouse.io/dynetherapeutics)
- **Growth Opportunity**: Joining a late‑stage biotech with a validated platform, strong cash position, and a clear path to commercialization – offering employees exposure to both R&D and upcoming launch activities.
- **Recruitment Scam Warning**: Dyne posts an explicit notice on its careers page that it never requests financial details or payment during hiring; all legitimate emails come from @dyne‑tx.com addresses.

## Sources
1. [dyne-tx.com – Company Overview](https://www.dyne-tx.com/)
2. [dyne-tx.com – Careers & Culture](https://www.dyne-tx.com/careers-culture/)
3. [dyne-tx.com – Pipeline](https://www.dyne-tx.com/pipeline/)
4. [investors.dyne-tx.com – Q4/Full Year 2025 Results](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
5. [linkedin.com – Dyne Therapeutics Company Profile](https://www.linkedin.com/company/dynetx)
6. [job-boards.greenhouse.io – Dyne Careers Page](https://job-boards.greenhouse.io/dynetherapeutics)

## Other roles at Dyne Therapeutics

- [Director, Government Pricing & Contract Operations](https://feeny.ai/job/director-government-pricing-contract-operations-dyne-therapeutics-waltham-jk69cejw4737) — Waltham, MA
- [Senior Director, Medical Affairs Biostatistics](https://feeny.ai/job/senior-director-medical-affairs-biostatistics-dyne-therapeutics-waltham-2f5wq33kjtjp) — Waltham, MA
- [Associate Director, Regulatory Operations - Veeva Vault RIM](https://feeny.ai/job/associate-director-regulatory-operations-veeva-vault-rim-dyne-therapeutics-6s40gy5y1631)
- [Director, Cost Accounting](https://feeny.ai/job/director-cost-accounting-dyne-therapeutics-waltham-k8qpf11tf80c) — Waltham, MA
- [Director, Revenue](https://feeny.ai/job/director-revenue-dyne-therapeutics-waltham-t62v02kw61st) — Waltham, MA
- [Associate Director, Market Research & Competitive Intelligence](https://feeny.ai/job/associate-director-market-research-competitive-intelligence-dyne-therapeutics-qc47ze0xw76k) — Waltham, MA
- [Associate Director, Medical Information and Review](https://feeny.ai/job/associate-director-medical-information-and-review-dyne-therapeutics-waltham-ff9hs10jh3sd) — Waltham, MA
- [Senior Director, Financial Planning & Analysis - R&D](https://feeny.ai/job/senior-director-financial-planning-analysis-r-d-dyne-therapeutics-waltham-64shts32jq8w) — Waltham, MA
- [Senior Administrative Assistant - US Affiliate](https://feeny.ai/job/senior-administrative-assistant-us-affiliate-dyne-therapeutics-waltham-y3emed522zqq) — Waltham, MA
- [Executive Assistant](https://feeny.ai/job/executive-assistant-dyne-therapeutics-waltham-f307nxzh29t2) — Waltham, MA